$1,000,000 dilution
Item 1.01. Entry into a Material Definitive Agreement.
On September 7, 2021, Rennova Health, Inc. (the “Company”) entered into the Securities Purchase Agreement, dated as of September 7, 2021 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Purchase Agreement provides for the issuance of up to 1,100 shares of Series O Convertible Redeemable Preferred Stock (the “Series O Preferred Stock”) at two closings of 550 shares each. If all such shares of Series O Preferred Stock are issued, the Company will receive proceeds of $1,000,000.